Ketofol Versus Dexmedetomidine for Prevention of Emergence Delirium in Pediatric Patients Undergoing Squint Surgeries
NCT ID: NCT06545890
Last Updated: 2024-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
46 participants
INTERVENTIONAL
2024-08-10
2024-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
KETODEX for Emergence Delirium in Children Undergoing Outpatient Strabismus Surgery
NCT03779282
Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
NCT01901588
The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery
NCT01512355
Gabapentin Oral Solution in Decreasing Desflurane Associated Emergence Agitation
NCT03347916
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
NCT00205712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• To compare the adverse effect profile associated with both drugs regarding the effect on heart rate, mean arterial pressure, recovery time, nausea, and vomiting.
Hypothesis
We hypothesize that Ketofol, due to the combined effect of ketamine and propofol will be as effective as dexmedetomidine in preventing ED in pediatric patients undergoing squint surgery.
Ethical Considerations
The study protocol will be implemented after the approval by the Institutional Research Ethics Committee and then written informed consent will be obtained from all patients before enrollment into the study.
Methodology
I. Study design
A prospective randomized controlled double blinded study.
II. Study setting and location
The study will be conducted at the Specialized Children Hospital (Abo El-Rish),
Cairo University.
III. Study population
All pediatric patients aged 2 to 6 years with ASA physical status I and II scheduled for squint surgery will be included in the study.
IV. Eligibility Criteria 1. Inclusion criteria
* All pediatric patients aged 2 to 6 years.
* Both sexes.
* ASA physical status I and II.
* Patients undergoing squint surgery.
2\. Exclusion criteria
* Refusal of parents.
* Patient sensitivity to any of the study medications.
* Known neurological disease that can affect the assessment of ED postoperatively.
V. Study Procedures 1. Randomization (in RCT only)
A computer-generated sequence will be used for randomization and opaque envelopes will be used for concealment.
The investigator is the anesthesiologist who will prepare all the syringes with the study drugs and will prepare them in wrapped aluminum foils and sealed opaque envelope technique. which will be provided to another investigator just before administering them to the children. Monitoring and data collection will be done by a resident who is unaware of the study drugs and allocation.
Study Protocol
All patients meeting the inclusion criteria will be assessed for adequate fasting (except for oral clear liquids intake 2 hours before surgery, all children will fast for 6 hours.). Patients will attend in the preparation room one hour before the operation to get a preoperative checkup, as well as their age and body weight will be recorded. Premedicated by intramuscular injection of atropine 0.02 mg/Kg and midazolam 0.2 mg/Kg. On arriving the operating room, standard monitors including SpO2, ECG, and noninvasive blood pressure ((Dräger infinity vista XL). will be applied. Inhalational induction using Sevoflurane 5% will be performed, and after the loss of consciousness intravenous cannula will be inserted. Atropine 0.01 mg/kg will be administered, and appropriate sized endotracheal tube will be inserted after muscle relaxation using atracurium 0.5 mg/kg. Maintenance of anesthesia using 2% Sevoflurane in 50% O2 will be started, and its dose will be adjusted according to the measured pulse and mean arterial pressure (MAP), which was kept within 20% of their basal values, with the goal of keeping the BIS measurement between (40-60) and atracurium top-ups of 0.1mg/kg was given every 30 minutes for neuromuscular blockade. and controlled ventilation will be applied, aiming for EtCO2 to be between 32-34 mmHg. using (G.E-Datex-Ohmeda, Avance CS2, USA) anesthesia machine. Then patients will be randomized to either group A or group B.
Group A:
Five minutes after securing the airway, dexmedetomidine infusion will be started at a rate of 0.2 mcg/kg/hr.
Group B:
Five minutes after induction; Ketofol (ketamine to propofol ratio 1:4) will be infused at a rate of 0.6 ml/kg/hr. Ketofol will be prepared by adding 40 mg of ketamine to 160 mg of propofol and diluted to 20 ml with normal saline 0.9%.
The hemodynamic data, including heart rate and arterial pressure, will be documented every five minutes and any intraoperative complications including bradycardia, hypotension will be managed and documented. Ten minutes before the conclusion of the surgery the infusion in both groups will be stopped. All patients will receive 15mg/kg paracetamol IV.
After finishing the surgical procedure, sevoflurane will be discontinued, and the neuromuscular block will be reversed via neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg). The patient will be extubated when he/she is fully awake, expressing eye-opening and purposeful movement, in addition to maintaining good tidal volume. Then, the patients will be transferred to the PACU, where they receive O2 via a face mask to maintain oxygen saturation above 95%.
During their stay at PACU, delirium will be assessed at 5, 10, 15, 20, 25, and 30 minutes following extubation via the Pediatric Anesthesia Emergence Delirium scale (PAED) (Table 1), and ED will be established when the child have a score of 10 or more. If the child has a score of 10 or more, rescue sedation will be done via propofol 1 mg/kg. (14,17)
The postoperative pain will be assessed via the Face, Legs, Activity, Cry, and Consolability (FLACC) scale 0 = Relaxed and comfortable,1-3 = Mild discomfort, 4-6 = Moderate pain, 7-10 = Severe discomfort/pain. IV Fentanyl (1 μgm /kg) will be administered if the child expressed a score of 3 or more. (16)
Criteria
Not at all
Just a little
Quite a bit
Very much
Extremely
Score
The child makes eye contact with the caregiver/parent.
4
3
2
1
0
The child's actions are purposeful.
4
3
2
1
0
The child is aware of his/her surrounding.
4
3
2
1
0
The child is restless.
0
1
2
3
4
The child is inconsolable.
0
1
2
3
4
Total score.
Table 1. Pediatric Anesthesia Emergence Delirium (PAED) Scale Score. The PAED scale consists of 5 criteria that are scored using a 5-point scale. The scores of each criterion are added to make a total score. The maximum achievable score is 20. A score of ≥10 has 64% sensitivity and 86% specificity for the diagnosis of ED. A score of \>12 100% sensitivity and 94.5% specificity for the diagnosis of ED (17).
Both pulse and MAP will be recorded at PACU on arrival, then at 5 and 10 minutes, then every 10 minutes until the discharge.
Any postoperative complications including bradycardia, hypotension or hypersensitivity reaction will be recorded. The incidence of postoperative vomiting, together with the duration of stay in PACU will be recorded.
Children were monitored in the PACU for all the above parameters until discharge and criteria of discharge are :
1. Fully awake
2. Calm
3. Stable hemodynamics
4. PAED scale \< 10
5. Oxygen saturation \> 92% on room air.
VI. Study outcomes
1. Primary outcome
The incidence of postoperative ED using PAED scale at time of admission to PACU in both groups.
2. Secondary outcome(s)
* Intraoperative vital signs So2 (%), HR (bpm) and MAP (mmhg) on admission to OR and every 5 minutes intraoperative.
* Incidence of Intraoperative complications (bradycardia and hypotension)
* PAED scale at 5, 10, 15, 20, 25 and 30 minutes after extubation.
* Total dose of rescue sedation by propofol (mg) at PACU.
* FLACC scale at PACU.
* Total dose of rescue analgesia (mic).
* Postoperative hemodynamics So2 (%), HR (bpm) and MAP (mmhg) after 5 and 10 minutes after admission to PACU then every 10 minutes till discharge.
* Incidence of postoperative nausea and vomiting.
* Length of stay in the PACU (minutes).
Statistical Analysis
I. Sample size
Sample size was calculated using G\*Power version 3.1.9.2 (Kiel University, Kiel, Germany) software; based on our primary outcome ED could occur in dexmedetomidine group and ketofol group with PAED score 1.55±2.195, and 4.70±3.988 respectively (8); a total sample of 46 patients (23 in each group) were required to achieve a power (1-β) of 90%, and type I α error of 0.05. Six patients were added to compensate for any drop out. Thus, the final sample was 26 patients in each group; with total 52 patients.
II. Statistical analysis
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketofol Group
Five minutes after induction; Ketofol (ketamine to propofol ratio 1:4) will be infused at a rate of 0.6 ml/kg/hr. Ketofol will be prepared by adding 40 mg of ketamine to 160 mg of propofol and diluted to 20 ml with normal saline 0.9%.
Ketamine
continous infusion during surgery
Dexmedetomidine
Five minutes after securing the airway, dexmedetomidine infusion will be started at a rate of 0.2 mcg/kg/hr.
Dexmedetomidine
continous infusion during surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketamine
continous infusion during surgery
Dexmedetomidine
continous infusion during surgery
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* ASA physical status I and II.
* Patients undergoing squint surgery.
Exclusion Criteria
* Patient sensitivity to any of the study medications.
* Known neurological disease that can affect the assessment of ED postoperatively.
2 Years
6 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Muhammad Khalaf
principle investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karim K Fahim
Role: STUDY_DIRECTOR
Professor of Anesthesia, Pain management and Surgical ICU Faculty of Medicine, Cairo University.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abu Elresh Hospitals ( Cairo university )
Cairo, , Egypt
Abu ElResh hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD-184-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.